


Anthony Waked^{1,2}, Koen Vermeulen¹, Bernard Rogister², Rafi Benotmane¹

¹Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium


²Laboratory of Nervous System Disorders and Therapy, GIGA Neurosciences, Université de Liège, Liège, Belgium

E-mail: anthony.waked@sckcen.be

Background




Objective




Results

Three CXCR4-targeting peptides are radiolabeled with Lu-177 and evaluated in U87-CXCR4 cells


Radiolabeling yield was measured using Instant Thin-Layer Chromatography (ITLC)




Detection of CXCR4 by western blot is challenging




To what extent can the radiolabeled peptides bind to and internalize into the cell?




Do the radiolabeled peptides bind specifically to CXCR4?




Are the radiolabeled peptides able to reduce the viability and proliferation of GBM cells?




Validation of 2Ig-B7-H3 overexpression in our cell model




Future Perspectives



Selection and further *in vitro* and *in vivo* evaluation of the CXCR4-targeted radiolabeled peptides



Production of nanobodies targeting B7-H3 at ULiège



For *in vivo* model, intracerebroventricular administration instead of intravenous?